ARS Pharmaceuticals (ARS Pharmaceuticals) Market Cap : $864.79 Mil (As of Jun. 03, 2024)

View and export this data going back to 2022. Start your Free Trial

What is ARS Pharmaceuticals Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). ARS Pharmaceuticals's share price for the quarter that ended in Mar. 2024 was $10.22. ARS Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 96.57 Mil. Therefore, ARS Pharmaceuticals's market cap for the quarter that ended in Mar. 2024 was $986.99 Mil.

ARS Pharmaceuticals's quarterly market cap increased from Sep. 2023 ($362.11 Mil) to Dec. 2023 ($528.35 Mil) and increased from Dec. 2023 ($528.35 Mil) to Mar. 2024 ($986.99 Mil).

ARS Pharmaceuticals's annual market cap increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($801.34 Mil) but then declined from Dec. 2022 ($801.34 Mil) to Dec. 2023 ($528.35 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. ARS Pharmaceuticals's Enterprise Value for Today is $636.05 Mil.

ARS Pharmaceuticals Market Cap Historical Data

The historical data trend for ARS Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARS Pharmaceuticals Market Cap Chart

ARS Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Market Cap

801.34

528.35

ARS Pharmaceuticals Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Market Cap	Get a 7-Day Free Trial							614.86	638.66	362.11	528.35	986.99

Competitive Comparison of ARS Pharmaceuticals's Market Cap

For the Biotechnology subindustry, ARS Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ARS Pharmaceuticals's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ARS Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where ARS Pharmaceuticals's Market Cap falls into.

ARS Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

ARS Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )	=	Share Price (A: Dec. 2023 )	*	Shares Outstanding (EOP) (A: Dec. 2023 )
	=	$5.48	*	96.415
	=	$528.35

ARS Pharmaceuticals's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )	=	Share Price (Q: Mar. 2024 )	*	Shares Outstanding (EOP) (Q: Mar. 2024 )
	=	$10.22	*	96.5741
	=	$986.99

ARS Pharmaceuticals (NAS:SPRY) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

ARS Pharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of ARS Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

ARS Pharmaceuticals (ARS Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARS Pharmaceuticals Inc (NAS:SPRY) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

N/A

Address

11682 El Camino Real, Suite 120, San Diego, CA, USA, 92130

Website

https://www.ars-pharma.com

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy (previously referred to as ARS-1) for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Executives

Alexander A Fitzpatrick	officer: Chief Legal Officer	9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121
Ra Capital Healthcare Fund Lp	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Laura Shawver	director, officer: Chief Executive Officer	1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vi Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter A. Thompson	director	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Brian Dorsey	officer: Chief Operating Officer	C/O SOMAXON PHARMACEUTICALS, INC., 10935 VISTA SORRENTO PARKWAY, SUITE 250, SAN DIEGO CA 92130
Kathleen D. Scott	officer: Chief Financial Officer	C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127
Pratik Shah	director, 10 percent owner	3366 N. TORREY PINES COURT, SUITE 220, LA JOLLA CA 92037
Jonathan S Leff	director	C/O DEERFIELD MANAGEMENT COMPANY, L.P, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Private Design Fund Iv, L.p.	director, 10 percent owner, other: * Director by deputization	780 THIRD AVENUE 37TH FLOOR, NEW YORK NY 10017
Deerfield Mgmt Iv, L.p.	director, 10 percent owner, other: * Director by deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Ra Capital Nexus Fund Ii, L.p.	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Brent L Saunders	director	2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033